Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7Sarcoma 6Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Liposarcoma, Myxoid 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Neurofibrosarcoma 2Melanoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Carcinoma, Intraductal, Noninfiltrating 2Advanced Refractory Solid Tumors 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Cancer Limited Stage 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myosarcoma 1Lymphatic Metastasis 1Lymphangiosarcoma 1Locally Recurrent Rectal Cancer 1

Interventions

pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Gemcitabine 1Cystectomy 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Infiltrating Bladder Urothelial Carcinoma × Radiation Dose Hypofractionation × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡